Compare Stocks: OXB and PRTC

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PRTC PureTech Health	$26.15	$26.40	$17.08 ▼ $34.00	$706.05M	1.23	3,386 shs	150 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PRTC PureTech Health	0.00%	+2.63%	-5.05%	+6.73%	-4.91%

Exposed: 10 CENT Crypto to Explode April 20th? (Ad)

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PRTC PureTech Health	0.151 of 5 stars	0.0	3.0	0.0	0.0	2.0	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PRTC PureTech Health	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PRTC PureTech Health	$15.62M	45.20	N/A	N/A	$19.64 per share	1.33

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PRTC PureTech Health	-$50.35M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	4/26/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
PRTC PureTech Health	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PRTC PureTech Health	111	27.00 million	25.56 million	Not Optionable

OXB and PRTC Headlines

Source	Headline
	PureTech Health (NASDAQ:PRTC) Shares Gap Down to $26.94 americanbankingnews.com - April 21 at 4:42 AM
	PureTech Health: Notice of Results businesswire.com - April 18 at 2:00 AM
	PureTech Health (NASDAQ:PRTC) Shares Gap Up to $25.48 marketbeat.com - April 17 at 2:15 PM
	PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis finance.yahoo.com - April 16 at 7:49 AM
	PureTech Health (NASDAQ:PRTC) Shares Gap Down to $27.93 americanbankingnews.com - April 14 at 2:52 AM
	US FDA hands fast track to PureTech head and neck cancer treatment lse.co.uk - April 11 at 8:26 AM
	PureTech's LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck Cancers markets.businessinsider.com - April 11 at 8:26 AM
	PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers businesswire.com - April 11 at 7:00 AM
	PureTech Health (NASDAQ:PRTC) Sees Unusually-High Trading Volume marketbeat.com - April 10 at 12:36 PM
	PureTech launches Seaport and changes CEO thepharmaletter.com - April 9 at 1:47 PM
	PureTech launches Seaport, hoping to create Karuna 2.0 biopharmadive.com - April 9 at 1:47 PM
	PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions businesswire.com - April 9 at 2:00 AM
	PureTech Health (NASDAQ:PRTC) Trading Down 5.9% marketbeat.com - April 5 at 1:28 PM
	PureTech Health (NASDAQ:PRTC) Sets New 52-Week High at $34.00 marketbeat.com - April 4 at 5:53 PM
	PureTech Health (NASDAQ:PRTC) Shares Gap Down to $30.00 marketbeat.com - April 2 at 11:18 AM
	PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable zacks.com - April 2 at 9:51 AM
	PureTech Health (NASDAQ:PRTC) Shares Gap Up to $28.50 marketbeat.com - April 1 at 5:30 PM
	PureTech Health (NASDAQ:PRTC) Shares Gap Down to $29.40 marketbeat.com - March 27 at 12:23 PM
	PureTech rewards shareholders with $100 million tender offer thepharmaletter.com - March 21 at 8:37 AM
	Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion businesswire.com - March 18 at 9:52 AM
	PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia finance.yahoo.com - March 13 at 8:41 AM
	AKLI Mar 2024 3.000 call finance.yahoo.com - February 28 at 1:37 PM
	PureTech notes positive results from Shionogi's EndeavorRx ADHD trial lse.co.uk - February 27 at 7:53 AM
	PureTech to Present at Two Upcoming Investor Conferences finance.yahoo.com - February 27 at 7:53 AM

Media Sentiment Over Time

Company Descriptions

PureTech Health

NASDAQ:PRTC

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Compare Stocks